Mitch Swarr and Charlie Creighton have wrestled every year of their high school careers. There wasn’t a whole lot the two hadn’t done when it comes to the wrestling mat, that is, until this offseason.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Our skin is constantly evolving, which means changes to our regiments are sometimes needed—especially when it comes to finding the best skin care routine for mature skin.

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

As a lover of puzzle games, what can elevate my puzzle-solving experience more than having horrifying monsters breathing down my neck and ready to snap said neck if I fail to solve their puzzle in ...

Starting the morning on the right foot can pave the way for a successful day. A new wellness trend focuses on the "5 to 9 before your 9 to 5," which entails a healthy regimen between the hours of 5 ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...